Drug intelligence / Profile preview

kpg-121 + apalutamide

Development stage: Unknown
Lead developer: Kangpu Biopharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

KPG-121 + apalutamide is a **combination therapy** consisting of KPG-121, a novel lenalidomide analogue and cereblon modulator, together with apalutamide, an androgen receptor antagonist. KPG-121 binds to the CRL4-Cereblon E3 ligase complex, promoting the rapid ubiquitination and degradation of casein kinase 1α (CK1α), as well as the transcription factors Aiolos (IKZF3) and Ikaros (IKZF1), resulting in immunomodulatory, anti-proliferative, and anti-angiogenic effects. Apalutamide antagonizes androgen receptor signaling, thereby inhibiting growth and survival of prostate cancer cells. This combination is being investigated primarily in **metastatic castration-resistant prostate cancer (mCRPC)**, with preclinical data showing enhanced anti-tumor activity when combining KPG-121 with apalutamide versus either agent alone. The developer of KPG-121 is Kangpu Biopharmaceuticals[1][2][3][5][8].

Brand names: Erleada (for apalutamide)
Other names: lenalidomide analogue + apalutamide

Targets

CK1α (Casein kinase I alpha)IKZF1 (Ikaros family zinc finger protein 1)AR (Adrenergic receptors)CRBN (Cereblon)IKZF3 (Zinc finger protein Aiolos)

Beyond the preview

Go deeper on kpg-121 + apalutamide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on kpg-121 + apalutamide.

Explore the full profile